Fujifilm is pouring 320,000 liters in North Carolina with one phase-two customer named

Fujifilm Biotechnologies' Holly Springs, North Carolina, site is on course for sixteen 20,000 L mammalian bioreactors and 1,400 staff by 2028, and so far one customer has been publicly named for the second half of it ^[3][4][5][6]. That is the current shape of the large-molecule market: the capacity a program will need at the end of the decade is being built now, and the scarce thing is a booked slot rather than a plant.

The arithmetic is worth doing slowly. Fujifilm first committed $2 billion for eight 20,000 L mammalian bioreactors at Holly Springs, then in 2024 added $1.2 billion for eight more by 2028, taking the site to $3.2 billion end to end, with the first phase opened last year ^[2][3][4]. Sixteen vessels at 20,000 L is 320,000 L of installed mammalian capacity at one address ^[1]. Add Hillerod, Denmark, which Fujifilm Corp. bought from Biogen in 2019 for $890 million and expanded in 2024 from six to twelve 20,000 L bioreactors, and the two large-scale sites reach 28 vessels and roughly 560,000 L ^[7][8][9][2].

The named demand behind phase two is argenx, which according to GEN has agreed to manufacture drug substance for efgartigimod alfa-fcab, sold as intravenous Vyvgart and, with hyaluronidase-qvfc, as injectable Vyvgart Hytrulo, in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy ^[6]. Between the 2024 announcement and the 2028 completion date there are about four years ^[4]. A sponsor negotiating today is contracting for suites that do not exist yet, and the slots fill during that window.

Headcount is the harder lead time. Holly Springs employs about 800 people and is set to reach 1,400 when phase two is done, which is 600 hires, a 75 percent increase ^[5][3]. The Hillerod expansion shows where that labor goes: a 2,000 square meter quality control laboratory opened ceremonially in April and began operations in May, staffed by roughly 100 quality personnel doing viral safety testing for drug substance and product release, cell-based potency and ELISA methods, and raw material and total organic carbon cleanability studies, inside a 7,600 square meter building with its own emergency generator ^[10][11][12]. "Simply, we needed more QC analytical capacities to support all the increased number of batches and the increased number of testing programs," Toshihisa Iida of Fujifilm told GEN ^[13]. Release testing scales with batches and programs, not with liters.

Iida also drew a line under further construction. His stated focus is getting existing facilities online and running well "because we already have big contracts with big clients," and any next-phase investment comes after more spending on people and quality systems ^[14]. Read plainly, the 28 vessels now committed are the supply for this cycle. Holly Springs was also one of seven facilities the FDA selected for its PreCheck Pilot Program ^[1]. Separately, the group's Fujifilm Cellular Dynamics opened a 175,000 square foot iPSC headquarters and manufacturing site in Madison, Wisconsin, in May, including a gene editing center of excellence ^[15].

What to watch: whether more phase-two customers are named before 2028, since an unfilled 320,000 L is a pricing event as much as a capacity one; whether Iida's operational-excellence condition holds and no third phase is announced ^[14]; and whether QC and analytical throughput, not bioreactor volume, becomes the queue that actually delays batches ^[13].